KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Enterprise Value (2017 - 2025)

Amneal Pharmaceuticals has reported Enterprise Value over the past 9 years, most recently at $48.4 million for Q4 2025.

  • Quarterly results put Enterprise Value at $48.4 million for Q4 2025, down 15.11% from a year ago — trailing twelve months through Dec 2025 was $48.4 million (down 15.11% YoY), and the annual figure for FY2025 was $48.4 million, down 15.11%.
  • Enterprise Value for Q4 2025 was $48.4 million at Amneal Pharmaceuticals, up from $33.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for AMRX hit a ceiling of $66.0 million in Q1 2025 and a floor of -$439.0 million in Q1 2021.
  • Median Enterprise Value over the past 5 years was $9.8 million (2021), compared with a mean of -$27.9 million.
  • Biggest five-year swings in Enterprise Value: plummeted 1231.64% in 2023 and later soared 13052.99% in 2025.
  • Amneal Pharmaceuticals' Enterprise Value stood at $8.0 million in 2021, then plummeted by 112.91% to -$1.0 million in 2022, then soared by 3384.13% to $33.7 million in 2023, then surged by 69.22% to $57.1 million in 2024, then fell by 15.11% to $48.4 million in 2025.
  • The last three reported values for Enterprise Value were $48.4 million (Q4 2025), $33.1 million (Q3 2025), and -$5.7 million (Q2 2025) per Business Quant data.